Cirino Botta

amazing #ASCO2026 presenting practice changing data from Majestec9 with Teclistamab vs SOC while sharing the stage with Italian friends and colleagues @Dagostino_MD @LucaBertamini Congrats to the maj9 team CTouzeau @HangQuach1 @dra_v_hungria @myelomaMD @thanosdimop @NBahlis

@RobertoMinaMD @PerrotAurore @mbeksac56 @DrOlaLandgren It is now clear that teclistamab, with or without daratumumab, is the new second-line standard of care in multiple myeloma. I'm curious to see whether this will ultimately reduce the role of cilta-cel, or if it will still retain a unique place in the treatment algorithm😎

@cirobotta2 @PerrotAurore @mbeksac56 @DrOlaLandgren

A higher GTL ratio improves daratumumab response and prolongs progression-free survival in patients with MM. BM-derived granulocytes are involved in the therapeutic activity of daratumumab. Read in Blood Neoplasia: ow.ly/Oz6350YpKWa #MultipleMyeloma #BoneMarrow

#Myeloma Paper of the Day: BM immune cell composition reflects myeloma progression & affects treatment response, w/ higher granulocyte-to-lymphocyte & granulocyte-to-T-lymphocyte ratios associated with improved PFS & outcomes w/ daratumumab therapy: pubmed.ncbi.nlm.nih.gov/41480309/. #mmsm

@alegozzetti, @paolapacelli93

Congratulations to Anna Maria Corsale and the entire research team! Another step forward in understanding how the immune system can help us in the fight against multiple myeloma and cancer in general... Ad Maiora! ashpublications.org/bloodneoplasia…

I am shook to the core. Only a day prior on stage with a legend. And me sneaking a selfie because I thought I was dreaming being on stage with this incredible man. We are all honored to stand on his shoulders to see cure on the horizon. A sad day for the world

@JoshuaRichterMD @RahulBanerjeeMD That’s such awful news.

MYELOMA2025 The Road to the Next Generation unipa.it/dipartimenti/p…

@PROMISE_UNIPA Tra 2 giorni si comincia!

It's day 2 of #IMS25! Begin your morning in Hall FG at 8:00 AM for the Industry Symposium, supported by GSK. Get ready for a day packed with exciting events—be sure to check the program! #IMS25 bit.ly/3K8T4QU

📢 Read research from our popular collection: Targeting the Microenvironment Niche in Hematologic Malignancies 🧑‍🔬Edited by Cirino Botta, Niccolo Bolli, Marco Rossi & Niels Weinhold Download your free copy here 👉fro.ntiers.in/RT11422

@NibitNetwork great presentation from Prof Gabrilovich in Palermo....MDSC time!

Are you at the @NibitNetwork Congress in Palermo today?🥼 Don't miss the Pezcoller Keynote Lecture! Dmitry Gabrilovich from @AstraZeneca will talk about myeloid cells in cancer: old challenges and new opportunities. 📌Today, at 4:30 PM 👉 pezcoller.it/en/scientific-…

New paper from my group!🎉🎉 Have you ever thought that detecting anti-CD38 mAbs through serum IFE could predict the outcome in MM? Look at these preliminary results! ehoonline.biomedcentral.com/articles/10.11…

#EHA2024 If PFS is similar in MRD negative patients at 10-6 regardless of treatment, it could become important to predict upfront whose patients can achieve MRD negativity with one regimen or other for individualized sequential treatment approaches #mmsm

@BrunoPaiva_UNAV And to de-escalate to regimens that could be better tolerated. Maybe, not every patient needs a quadruplet...

🟠 Vacante para estudiante predoctoral 🟠 Buscamos una persona para desarrollar su doctorado en el laboratorio de Hematología Traslacional, dirigido por @BrunoPaiva_UNAV. 👨‍🔬 ¿Quieres formar parte de nuestro equipo? 👩‍🔬 🔎 Más información y otras ofertas: cima.cun.es/trabaje-con-no…

@NBahlis @NatureMedicine Congratulations Nizar!!!! Another super paper!!! You are doing an incredible work!!! Fantastic😄😁

Out in today @NatureMedicine, nature.com/articles/s4159… FIH phase 1 trial with Elranatamab in R/R multiple myeloma defining the RP2D. High (ORR 64%) including in patients with high risk cytogenetics and prior anti-BCMA exposure. Responses were durable (DOR 17.1 mod, PFS 11.8 mod).